Rodney Snow, MD
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1770798506
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $145,993 of the $180,651 with a category attached, or 80.8%. 34 manufacturers reported payments, led by Ascendis Pharma Endocrinology Inc at 48.6% of the total. 2025 is the largest year on record at $91,214, 3.5 times the $25,801 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,020 payments — averaging $177.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$88K
- Mannkind Corporation$34K
- Medtronic$21K
- Shire North American Group Inc$15K
- Insulet Corporation$7K
- Zealand Pharma US, Inc.$3K
- plus $11K from 28 others
Across 21 payments — averaging $367.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$8K
What the payments were for
- Consulting fees$1,7001%
- Speaking & faculty fees$145,99381%
- Travel & lodging$14,1508%
- Food & beverage$18,71110%
- Education$390%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 71 | $87,719 |
| Mannkind Corporation | 318 | $34,460 |
| Medtronic | 51 | $21,482 |
| Shire North American Group Inc | 23 | $15,046 |
| Insulet Corporation | 43 | $7,375 |
| Zealand Pharma US, Inc. | 7 | $3,219 |
| Novo Nordisk | 89 | $1,896 |
| Lilly USA, LLC | 87 | $1,783 |
| Abbott | 105 | $1,559 |
| Cequr Corporation | 4 | $944 |
| Boehringer Ingelheim | 40 | $861 |
| Xeris Pharmaceuticals, Inc. | 25 | $539 |
| Companion Medical, Inc. | 1 | $500 |
| Amgen | 36 | $487 |
| Sanofi-aventis U.S. LLC | 24 | $438 |
| BETA Bionics, Inc. | 20 | $396 |
| Tandem Diabetes Care, Inc. | 9 | $383 |
| Sequel Med Tech, LLC | 8 | $274 |
| Amneal Pharmaceuticals LLC | 12 | $215 |
| Corcept Therapeutics | 10 | $197 |
| AstraZeneca | 4 | $193 |
| Dexcom, Inc. | 4 | $135 |
| IBSA Pharma Inc. | 5 | $97 |
| AbbVie | 6 | $90 |
| Amphastar Pharmaceuticals, Inc. | 4 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $75 |
| Ascensia Diabetes Care US Inc. | 3 | $70 |
| Bigfoot Biomedical Inc | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Senseonics, Incorporated | 1 | $24 |
| GSK | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| Nevro Corp. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yorvipath$83,669
- AFREZZA$30,328
- NATPARA (PARATHYROID HORMONE)$14,603
- InPen$11,875
- Omnipod$6,684
- INPEN SMART INSULIN DELIVERY SYSTEM$6,480
- ZEGALOGUE$3,077
- Minimed 770G System$2,813
- CeQur Simplicity$944
- MINIMED 780G$149
- RYBELSUS$147
- Ozempic$147
- TWIIST$130
- FARXIGA$120
- t-slim insulin pump$105
How this compares
$180,651 in reported general payments places this provider in the 90th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $108,535 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 65 | $89,706 |
| MounjaroTirzepatide | 36 | $46,857 |
| JardianceEmpagliflozin | 28 | $45,417 |
| Teriparatide | 13 | $30,196 |
| FarxigaDapagliflozin Propanediol | 26 | $23,143 |
| TrulicityDulaglutide | 24 | $22,533 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $19,528 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $9,168 |
| NovologInsulin Aspart | 26 | $8,542 |
| Novolog FlexpenInsulin Aspart | 37 | $7,023 |
| SynthroidLevothyroxine Sodium | 75 | $6,986 |
| HumalogInsulin Lispro | 33 | $6,458 |
| Levothyroxine Sodium | 354 | $4,770 |
| Insulin Aspart FlexpenInsulin Aspart | 12 | $3,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,896 | $117,07795 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,783 | $75,84993 claims |
| Boehringer IngelheimJardiance | $861 | $45,41728 claims |
| AstraZenecaFarxiga | $193 | $23,14326 claims |
| AbbVieSynthroid | $90 | $6,98675 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $215 | $4,770354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Nashville
- Craig WierumNashville$1.3M
- Terri JerkinsNashville$567K
- Michael CarlsonNashville$381K
- Kathryn DahirNashville$225K
- Annis MarneyNashville$26K
- Emily NeelyNashville$21K
- Amanda DanielNashville$20K
- Juliana MatthewsNashville$15K
- Christopher BowmanNashville$14K
- Cheryl FasslerNashville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.